
About Castle Creek Pharma
Castle Creek Pharma is a Healthcare company based in Basking Ridge (United States) founded in 2015. Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders. Castle Creek Pharma has raised $663.15 million across 3 funding rounds from investors including Fidelity Investments and Valor Equity Partners. The company has 72 employees. Castle Creek Pharma has completed 1 acquisition, including Fibrocell Science. Its chief executive, as recorded, is Matthew Gantz. Its focus areas include Life Sciences, Rare Diseases, Drugs and Dermatological Diseases. Its competitors include Castle Creek Biosciences, Eicos Sciences and LifeMax; 1 of its 3 listed competitors has raised funding.
Company details
Castle Creek Pharma, part of Paragon Biosciences, is developing drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders (UCDs). Its drug pipeline includes CCP-020 (diacerein 1 ointment) for the treatment of Epidermolysis Bullosa Simplex (Phase 3); CCP-040 which is in development for the treatment of oral and head and neck cancers (preclinical), as an adjuvant therapy to prevent recurrence; CCP-010, a molecular chaperone that is being developed as the first treatment option for patients with GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease), a lysosomal storage disorder (Phase 23); CCP-110, in development for the treatment of hyperammonemia in UCDs (Phase 12) that acts by trapping ammonia ions in the gut and rapidly excreting them from the body.
- Headquarters Basking Ridge, United States
- Employees 72
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website castlecreekpharma.com
- Social LinkedIn X Facebook
- Total Equity Funding$663.15M (USD)
in 3 rounds
- Latest Funding Round$54.6M (USD), Series C
Dec 2019
- InvestorsFidelity Investments
& 1 more
- Employee Count72
- Investments & Acquisitions
Funding Insights of Castle Creek Pharma
Castle Creek Pharma has successfully raised a total of $663.15M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $54.6 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $663.15M
- Total Rounds 3
- Last Round Series C β $54.6M
- First Round $48M
(Oct 2016)
- Investors Count 2
All 3 funding rounds of Castle Creek Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $54.6M | Series C | β | β | β |
| Oct 2018 | $560.54M | Series C | β | Fidelity Investments, Valor Equity Partners | β |
| Oct 2016 | $48M | Series B | β | Fidelity Investments | β |
2 investors in total: 2 institutional.
Investors in Castle Creek Pharma
Castle Creek Pharma has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments and Valor Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm | valorep.com | Chicago, United States | ||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States |
Investor details for Castle Creek Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Castle Creek Pharma
1 people are tracked at Castle Creek Pharma (1 in leadership); the tracked headcount is 72.
| Name | Role | Group |
|---|---|---|
Matthew Gantz | CEO | Leadership |
Complete people profiles for Castle Creek Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Castle Creek Pharma
Castle Creek Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fibrocell Science.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of autologous cell and gene therapies for diseases of the skin, connective tissue and joints | fibrocell.com | Exton, United States | 1995 | Sep 2019 | $63.3M |
Complete acquisition details for Castle Creek Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Castle Creek Pharma
4 dated milestones of Castle Creek Pharma across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Castle Creek Pharma is founded.
- Funding First funding round of $48.0M.
- Acquisition Acquires Fibrocell Science.
- Funding Latest funding round, Series C, of $54.6M.
Competitors of Castle Creek Pharma
Castle Creek Pharma has 3 listed competitors in our database, 1 of them funded. They include Castle Creek Biosciences, Eicos Sciences and LifeMax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| castlecreekbio.com | 2018 | Exton, United States | $192.8M | 41 | Gene therapy platform for rare disease treatments is developed. | |
| eicossciences.com | 2016 | San Mateo, United States | 9 | Develops Prostacyclin-based therapies for underserved medical conditions globally. | ||
| lifemaxlabs.com | 2014 | Redwood, United States | Develops innovative therapeutic solutions for Netherton syndrome treatment. |
Detailed competitors of Castle Creek Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Castle Creek Pharma (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Castle Creek Pharma
Complete news archive for Castle Creek Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Castle Creek Pharma
Castle Creek Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Castle Creek Pharma is headquartered in Basking Ridge, United States. It is registered at Basking Ridge, New Jersey, United States.
Matthew Gantz is the CEO of Castle Creek Pharma, as recorded in our data.
Castle Creek Pharma is a funded company, having raised a total of $663.15M across 3 funding rounds to date. The company's 1st funding round was a Series B of $48M, raised on Oct 2016.
Castle Creek Pharma has 72 employees.
Castle Creek Pharma, part of Paragon Biosciences, is developing drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders (UCDs). Its drug pipeline includes CCP-020 (diacerein 1 ointment) for the treatment of Epidermolysis Bullosa Simplex (Phase 3); CCP-040 which is in development for the treatment of oral and head and neck cancers (preclinical), as an adjuvant therapy to prevent recurrence; CCP-010, a molecular chaperone that is being developed as the first treatment option for patients with GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease), a lysosomal storage disorder (Phase 23); CCP-110, in development for the treatment of hyperammonemia in UCDs (Phase 12) that acts by trapping ammonia ions in the gut and rapidly excreting them from the body.
Castle Creek Pharma's top competitors include Castle Creek Biosciences, Eicos Sciences and LifeMax.
Castle Creek Pharma has made 1 acquisition, including Fibrocell Science.
Castle Creek Pharma has 2 investors. Key investors include Fidelity Investments, and Valor Equity Partners.
